Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 23;11(13):3625.
doi: 10.3390/jcm11133625.

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall

Sabina Ugovšek  1 , Miran Šebeštjen  1   2   3
Affiliations
Review

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall

Sabina Ugovšek et al. J Clin Med. .

Abstract

Elevated low density lipoprotein (LDL) cholesterol and lipoprotein(a) (Lp(a)) levels have an important role in the development and progression of atherosclerosis, followed by cardiovascular events. Besides statins and other lipid-modifying drugs, PCSK9 monoclonal antibodies are known to reduce hyperlipidemia. PCSK9 monoclonal antibodies decrease LDL cholesterol levels through inducing the upregulation of the LDL receptors and moderately decrease Lp(a) levels. In addition, PCSK9 monoclonal antibodies have shown non-lipid effects. PCSK9 monoclonal antibodies reduce platelet aggregation and activation, and increase platelet responsiveness to acetylsalicylic acid. Evolocumab as well as alirocumab decrease an incidence of venous thromboembolism, which is associated with the decrease of Lp(a) values. Besides interweaving in haemostasis, PCSK9 monoclonal antibodies play an important role in reducing the inflammation and improving the endothelial function. The aim of this review is to present the mechanisms of PCSK9 monoclonal antibodies on the aforementioned risk factors.

Keywords: PCSK9 monoclonal antibodies; coagulation; endothelial dysfunction; fibrinolysis; haemostasis; inflammation; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
The role of PCSK9 in inflammation process. PCSK9 induces the expression of VEGF-A and ICAM-1 and, consequently, activates endothelial cells and stimulates monocyte/macrophage migration. The cascade promotes an inflammatory state and the progression of the atherosclerotic process. On the other hand, anti-inflammatory cytokines such as IL-10 attenuate the inflammatory response. PCSK9, proprotein convertase subtilisin/kexin type 9; VEGF-A, vascular endothelial growth factor A; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; TNF-α, tumor necrosis factor-α.
Figure 2
Figure 2
The role of PCSK9 in platelets’ activity. High PCSK9 levels enhance platelet activation and reduce platelet responsiveness to acetylsalicylic acid, thus promoting atherosclerotic events. ASA, acetylsalicylic acid.
Figure 3
Figure 3
The role of PCSK9 in coagulation and fibrinolysis. PCSK9 induces the production of tissue factor, which is responsible for the activation of the extrinsic coagulation pathway and thrombus formation. TF, tissue factor; PAI-1, plasminogen activator inhibitor-1; F VIII, factor VIII.
See this image and copyright information in PMC

References

    1. Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaaway C.W., Carson A.P., Chamberlain A.M., Chang A.R., Cheng S., Das S.R., et al. Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation. 2019;139:e1–e473. doi: 10.1161/CIR.0000000000000659. - DOI - PubMed
    1. Krychtiuk K.A., Kastl S.P., Wojta J., Speidl W.S. Inflammation and coagulation in atherosclerosis. Hämostaseologie. 2013;33:269–282. doi: 10.5482/HAMO-13-07-0039. - DOI - PubMed
    1. Borén J., Chapman M.J., Krauss R.M., Packard C.J., Bentzon J.F., Binder C.J., Daemen M.J., Demer L.L., Hegele R.A., Nicholls S.J., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2020;41:2313–2330. doi: 10.1093/eurheartj/ehz962. - DOI - PMC - PubMed
    1. Elshourbagy N.A., Meyers H.V., Abdel-Meguid S.S. Cholesterol: The Good, the Bad, and the Ugly—Therapeutic Targets for the Treatment of Dyslipidemia. Med. Princ. Pract. 2013;23:99–111. doi: 10.1159/000356856. - DOI - PMC - PubMed
    1. Krychtiuk K.A., Lenz M., Hohensinner P., Distelmaier K., Schrutka L., Kastl S.P., Huber K., Dostal E., Oravec S., Hengstenberg C., et al. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. J. Clin. Lipidol. 2021;15:512–521. doi: 10.1016/j.jacl.2021.02.005. - DOI - PubMed

LinkOut - more resources